PIK3CD and hematopoietic and lymphoid cell neoplasm: The relationship of p110δ PI3K with cancer had received much less attention but recently p110δ has entered the realm of hematologic cancers and p110δ-selective inhibitors have provided promising results in some hematological malignancies (Fruman and Rommel, 2011; Castillo et al., 2012).